"This agreement highlights Galderma's commitment to the future of dermatology. Aganocide compounds have the potential to bring about significant progress in the treatment of skin diseases which affect millions of patients, without adding to the growing problem of antibiotic resistance," said Humberto C. Antunes, Chief Executive Officer of Galderma. "Galderma is glad to be working with NovaBay in this important and very promising endeavor."
"We are very pleased to have entered into this collaboration with Galderma, the world-leader in dermatology. We believe that Galderma's demonstrated development, regulatory and marketing capabilities, backed by its unrivaled reputation and track record of success, will enable NovaBay to benefit from accelerated development timelines and global commercial expertise," said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay. "Like our alliance with Alcon in the ophthalmic, otic and sinus fields, this agreement represents another major validation of the potential for our novel Aganocide products in treating infections caused by a wide range of bacteria, viruses and fungi."
The company's collaborations with Alcon and Galderma provide significant future revenue-generating potential for NovaBay, with favorable economic-sharing for its unique, differentiated products that address large, global dermatological and ophthalmic markets.
NovaBay will hold a conference call today, March 25, 2009 at 11:00 a.m. ET, to discuss its Galderma collaboration. The conference call will be simultaneously web cast on NovaBay's web site.
Conference call details: Date: Wednesday, March 25, 2009 Time: 11:00 a.m. ET Dial-in (U.S.): 888-396-2384 Dial-in (International): 617-847-8711 Web cast:
|SOURCE NovaBay Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved